Alerta

WEARABLE DEVICE SUCH AS FOR GLUCOSE MEASUREMENT

Resumen de: US2025272940A1

Modulation-encoded light, using different spectral bin coded light components, can illuminate a stationary or moving (relative) target object or scene. Response signal processing can use information about the respective different time-varying modulation functions, to decode to recover information about a respective response parameter affected by the target object or scene. Electrical or optical modulation encoding can be used. LED-based spectroscopic analysis of a composition of a target (e.g., SpO2, glucose, etc.) can be performed; such can optionally include decoding of encoded optical modulation functions. Baffles or apertures or optics can be used, such as to constrain light provided by particular LEDs. Coded light illumination can be used with a focal plane array light imager receiving response light for inspecting a moving semiconductor or other target. Encoding can use orthogonal functions, such as an RGB illumination sequence, or a sequence of combinations of spectrally contiguous or non-contiguous colors.

TRANSDERMAL GLUCOSE MONITOR COVER

Resumen de: US2025268491A1

A cover apparatus for obstructing a transdermal glucose monitor from view includes a top wall shaped and a perimeter wall. The perimeter wall is coupled to and extends away from the top wall. The perimeter wall and the top wall define a cavity which is dimensioned and configured to receive the transdermal glucose monitor therein

INFUSION DEVICES AND RELATED RESCUE DETECTION METHODS

Resumen de: US2025269113A1

Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver fluid to a body of a user involves obtaining measurement values for a physiological condition influenced by the fluid, autonomously operating the infusion device to deliver the fluid based at least in part on the measurement values, and detecting a nonactionable condition based on the measurement values. In response to detecting the nonactionable condition, delivery of the fluid is limited while maintaining autonomous operation of the infusion device. In one exemplary embodiment, the nonactionable condition is a rescue condition indicative of the user having consumed fast-acting carbohydrates, and thus insulin delivery may be automatically limited in response to detecting the rescue carbohydrate consumption.

ACTIVE FANO RESONANCE BLOOD GLUCOSE SENSOR

Resumen de: WO2025175641A1

An active Fano resonance blood glucose sensor, relating to the field of non-invasive blood glucose monitoring. The blood glucose sensor comprises a resonator, an excitation layer, a low-noise amplifier (8) and a phase shifter (9), wherein the resonator, the low-noise amplifier (8) and the phase shifter (9) form a connection loop; the resonator is provided on the excitation layer; and the excitation layer is connected to an external excitation source. By using the phase shifter (9), the phase of an active circuit can be changed to selectively enhance resonance, improve the resonance Q factor, and realize detection of minor changes in blood glucose concentration, and thus the active Fano resonance blood glucose sensor can be applied to human blood glucose sensing and the problems in the prior art of poor stability and robustness. Moreover, by using the resonator and the excitation layer, self-reference error elimination can be achieved, significantly improving the performance of the microwave blood glucose sensor and improving the reliability of blood glucose measurement.

WEARABLE NONINVASIVE MICROWAVE GLUCOMETER

Resumen de: WO2025175650A1

The present disclosure relates to the field of noninvasive glucose monitoring, and specifically, to a wearable noninvasive microwave glucometer. According to the present disclosure, an active Fano resonance-based glucose sensor (11) and a glucose monitoring system (12) are integrated, such that the whole noninvasive microwave glucometer features compactness, wearability, and high sensitivity. Moreover, the active Fano resonance-based glucose sensor (11) monitors the blood glucose concentration on the basis of a microwave signal generated by a microwave signal generation-processing unit, and can thus achieve noninvasive, real-time glucose monitoring in a human and hypoglycemia alarm. The arrangement of the active Fano resonance-based glucose sensor (11), a power supply unit (14), the microwave signal generation-processing unit, and a screen (15) can improve the resolution and sensitivity of blood glucose monitoring, thereby meeting the clinical precision requirements.

AUTOMATIC MEDICAMENT DELIVERY DEVICE UTILIZING LIMITED OR NO USER INPUT

Resumen de: WO2025178832A1

Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.

ANALYTE SENSORS AND SENSING METHODS FEATURING DUAL DETECTION OF GLUCOSE AND KETONES

Resumen de: EP4606303A1

Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.

Investigation of glycemic events in blood glucose data

Resumen de: US12396664B1

To better understand the impact of glycemic events, some entities have begun examining the relationship between the blood glucose level and another physiological parameter. However, this relationship can be difficult to understand. Introduced here are computer programs and associated computer-implemented techniques for discovering glycemic events in a series of data values representative of blood glucose measurements and then altering the measurement schedule of a sensor capable of generating measurements in a dimension other than blood glucose based on the glycemic events. By altering the measurement schedule of the sensor, a diabetes management platform can better understand how, if at all, dimensions other than blood glucose are related to the glycemic health state of a subject whose blood glucose level is being monitored.

ANALYTE LEVEL CALIBRATION USING BASELINE ANALYTE LEVEL

Resumen de: US2025261885A1

Methods, computers, and systems used to improve accuracy of glucose level measurement of an in vivo positioned sensor are disclosed herein. The method includes collecting signal data from an in vivo positioned sensor over a period of time, wherein the signal data is indicative of glucose levels, analyzing the collected signal data and identifying signal data points that occur most frequently within the collected data, correlating the identified signal data points to a normal physiological level for glucose, the identified signal data points being taken from the signal data collected from the in vivo positioned sensor, and deriving glucose levels from the collected signal data using the identified signal data points as a reference point for the normal physiological level of the glucose for a user of the in vivo positioned sensor

AUTOMATIC MEDICAMENT DELIVERY DEVICE UTILIZING LIMITED OR NO USER INPUT

Resumen de: US2025262379A1

Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.

ADJUSTING INSULIN DELIVERY RATES

Resumen de: US2025262381A1

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.

WATERPROOF CASING FOR INSULIN PUMPS

Resumen de: WO2025175025A1

A casing for an insulin delivery system includes a housing, a lid, and a gasket. The housing includes a first overmolded rubber member defining a first channel part. The lid includes a second overmolded rubber member defining a second channel part. The lid is couplable to the housing to define an enclosure and a cavity. The enclosure is configured to receive an insulin pump. The cavity receives the rubber members such that the channel parts define a channel when the lid is removably coupled to the housing. The channel encloses a tubing to fluidly couple the insulin pump to an outside of the casing. The gasket is received between the housing and the lid to seal the housing with the lid, preventing fluid ingress into the cavity and the enclosure and providing a waterproof seal between the cavity and the enclosure when the lid is removably coupled to the housing.

BLOOD GLUCOSE PREDICTION METHOD AND DEVICE COMBINING BIG DATA MODEL AND PERSONALIZED MODEL

Resumen de: US2025266171A1

A blood glucose prediction method includes training a prediction model; receiving a first data set of an object; when a first data type is a label, updating a personalized database; counting the personalized data records to generate a first total number; if the first total number is greater than or equal to a first threshold value, screening personalized data calibrated records; if the first total number is equal to a second threshold value, training a personalized prediction model; when the first data type is a prediction, counting the personalized data records to generate a second total number; if the second total number is smaller than the second threshold value, based on the prediction model, making a prediction; and if the second total number is equal to the second threshold value, based on the prediction model and the personalized prediction model, making a personalized prediction.

SYSTEM AND METHOD FOR PROVIDING ALERTS OPTIMIZED FOR A USER

Resumen de: US2025266143A1

Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.

FLEXIBLE ELECTRONICS FOR ANALYTE DETECTION

Resumen de: US2025261881A1

A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose-responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.

Methods For Reduction of Battery Usage In Ambulatory Infusion Pumps

Resumen de: US2025267580A1

A battery-powered infusion pump for medicament delivery (e.g., insulin) may collect and store data related to the pump. The infusion pump can communicate some or all of the stored data to another device and control the timing and amount of data communicated in order to conserve battery life.

Apparatus, methods and computer programs for detecting critical events

Resumen de: GB2638147A

A system 100 comprises a number of devices 102 in communication with one another. The devices 102 are associated with a user 104 and may comprise a smartphone 102A, wearable devices such as a headset 102B or heart rate monitor 102C, and other local devices 102D,102E such as smart speakers including a microphone, cameras, motion sensors or other devices used for monitoring the area around the user 104. The wearable devices may comprise sensors for monitoring physiological parameters or an IMU for monitoring position or movement of the user 104. One or more of the devices 102 can be configured to detect a critical event. A critical event is an event considered to be dangerous or causes the user to require assistance such as cardiac events, a drop in blood sugar level, or a fall. If a critical event occurs, one or more of the devices 102 can raise an alarm or contact assistance. Before such takes place, the system confirms that a prospective critical event is an actual critical event by obtaining additional data from another device 102 in the system. This can help to avoid false alarms or other calls for assistance being raised unnecessarily.

COMPOSITIONS FOR GLUCOSE-RESPONSIVE DRUG DELIVERY SYSTEMS VIA MULTIFUNCTIONAL HYDROGEL-BASED MICRONEEDLE

Resumen de: WO2024077402A1

The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa ~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.

ELECTRONIC APPARATUS AND CONTROLLING METHOD THEREOF

Resumen de: EP4604136A1

A method performed by an electronic apparatus is disclosed. The method comprises receiving information about a user's glucose concentration from an analyte monitoring device attached to the user's body, receiving an alert condition set by a follower of the user at the follower's device, determining whether the alert condition is satisfied based on the information about the user's glucose concentration, and controlling the follower's device to output an alert when the alert condition is satisfied.

RETROSPECTIVE RETROFITTING METHOD TO GENERATE A CONTINUOUS GLUCOSE CONCENTRATION PROFILE

Resumen de: EP4603003A2

Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a "retrofitting" algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting algor

INTRAVASCULAR ARTIFICIAL PANCREAS

Resumen de: AU2024219128A1

Disclosed herein are intravascular artificial pancreas devices and methods for their manufacture.

MACHINE-LEARNING-BASED MEAL DETECTION AND SIZE ESTIMATION USING CONTINUOUS GLUCOSE MONITORING (CGM) AND INSULIN DATA

Resumen de: US2025259727A1

Disclosed is a meal detection and meal size estimation machine learning technology. In some embodiments, the techniques entail applying to a trained multioutput neural network model a set of input features, the set of input features representing glucoregulatory management data, insulin on board, and time of day, the trained multioutput neural network model representing multiple fully connected layers and an output layer formed from first and second branches, the first branch providing a meal detection output and the second branch providing a carbohydrate estimation output; receiving from the meal detection output a meal detection indication; and receiving from the carbohydrate estimation output a meal size estimation.

METHOD FOR MANAGING MEDICAL DATA

Resumen de: US2025259720A1

This disclosure relates to a method, a mobile device, and a computer program, for managing medical data such as, e.g., glucose concentrations, by an electronic disease management system. In the method a change of the local time between generation of a first set of medical data and a second set of medical data is detected.

SYSTEM AND METHOD FOR ADJUSTING INSULIN DELIVERY

Resumen de: US2025256027A1

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and/or determining one or more user specific dosage parameters.

BLOCKAGE DETECTION DEVICE FOR DIABETIC INSULIN INJECTION PUMP

Nº publicación: LU600247B1 14/08/2025

Solicitante:

WUXI MATERNAL AND CHILD HEALTH HOSPITAL [CN]
WUXI MATERNAL AND CHILD HEALTH HOSPITAL

Resumen de: LU600247B1

The invention belongs to the technical field of pressure monitoring, in particular to a blockage detection device for a diabetic insulin injection pump, which comprises a gun shell, wherein an injection refill is arranged in the barrel of the gun shell, a refill piston is arranged in the injection refill, an injection pipeline is arranged at one end of the injection refill near the muzzle of the gun shell, the injection pipeline extends out of the gun shell; one side of the refill piston near the injection pipeline is provided with a membrane pressure sensor, a driving mechanism for driving the refill piston to move is arranged inside the gun body of the gun shell; a handle of the gun shell is provided with a manual switch assembly, a controller, a blood sugar monitoring module and an alarm prompt system.